AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Condition(s) studied
Investigational drug(s) / intervention(s)
IMPEDE-FX RapidFill Implants: Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants
EndoVascular Aneurysm Repair: Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
Study summary
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Eligibility
Primary outcome measure(s)
- Primary Effectiveness Endpoint : AAA Sac Regression at 1 year — 1 year
The percentage of subjects showing regression, defined as sac volume reduction of ≥10% at 1 year (in comparison to the 30 day CT), and no AAA-related intervention through 1 year. - Primary Safety Endpoint : Major Adverse Event (MAE) Rate through 30 days — 30 days
Freedom from the following through 30 days post-index procedure: * Major adverse events (MAEs) which include the following: all-cause mortality, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, procedural blood loss \>1000 mL. * AAA-rupture or AAA-perforation * Conversion to Open Repair
Trial sites (49)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | |
| Honor Health | Scottsdale | Arizona | |
| USC Keck | Los Angeles | California | |
| San Diego VA Medical Center | San Diego | California | |
| Delray Medical Center | Delray Beach | Florida | |
| Mt. Sinai Medical Center | Miami Beach | Florida | |
| Orlando Health | Orlando | Florida | |
| University of South Florida | Tampa | Florida | |
| Emory University Hospital | Atlanta | Georgia | |
| University of Chicago | Chicago | Illinois | |
| Indiana University | Indianapolis | Indiana | |
| Maine Medical | Portland | Maine | |
| Johns Hopkins | Baltimore | Maryland | |
| Massachusetts General Hospital | Boston | Massachusetts | |
| Brigham & Women's Hospital | Boston | Massachusetts | |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | |
| VA Ann Arbor Healthcare | Ann Arbor | Michigan | |
| Corewell Health | Grand Rapids | Michigan | |
| Mayo Clinic | Rochester | Minnesota | |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | |
| University at Buffalo | Buffalo | New York | |
| Buffalo VA Western New York | Buffalo | New York | |
| NYU Langone | New York | New York | |
| Columbia University Irving Medical Center/New York Presbyterian Hospital | New York | New York | |
| University of Rochester | Rochester | New York | |
| Stony Brook Medicine | Stony Brook | New York | |
| TriHealth Heart Institute | Cincinnati | Ohio | |
| Ohio State University Wexner Medical Center | Columbus | Ohio | |
| The Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | |
| Sanford Health | Sioux Falls | South Dakota | |
| Vanderbilt University | Nashville | Tennessee | |
| St. David's Healthcare | Austin | Texas | |
| Houston Methodist | Houston | Texas | |
| Baylor Scott and White | Plano | Texas | |
| The University of Texas Health Science Center at San Antonio | San Antonio | Texas | |
| University of Virginia | Charlottesville | Virginia | |
| Inova Schar Heart and Vascular | Falls Church | Virginia | |
| Sentara Norfolk General | Norfolk | Virginia | |
| University of Wisconsin | Madison | Wisconsin | |
| Hopital Cardiologie | Lille | Hauts-de-France |
+ 9 more sites — see the full list on the official registry below.
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06029660 on ClinicalTrials.gov ↗ ← All trials in France